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Strengths and limitations of this study
 ► For the first time, we have examined to what extent 
contemporary protocols describe systematic liter-
ature searches and use the results to inform trial 
design.
 ► We performed our own searches to identify any rel-
evant trials that could have been cited.
 ► Our sample only contain trials approved in Denmark 
and the sample size was not large enough to per-
form inferential statistics.
 ► The legal regulation has changed since the proto-
cols in our sample were approved, meaning that the 
ethical committees now have access to the inves-
tigator’s brochure (a document containing clinical 
information on the studied intervention) which could 
be important for our conclusions.
AbStrACt
Objective To investigate to what extent evidence 
from previous similar trials or systematic reviews was 
considered before conducting new trials.
Design Cohort study of contemporary protocols for trials 
with ethical approval.
Methods All protocols for randomised trials approved by 
the five ethical committees in Denmark between January 
2012 and March 2013 were screened for eligibility. 
Included protocols were read in full to determine whether 
a systematic search had been conducted and references 
were checked to evaluate whether trial rationale and 
design could be challenged for not adequately considering 
previous evidence. To investigate whether protocols cited 
relevant trials, we used simple search strategies that could 
easily be conducted by researchers without experience 
with literature searches.
results Sixty- seven protocols were included. Only 
two (3%) of the protocols explicitly stated to have 
conducted a literature search and only one (1%) provided 
information that allowed the search to be replicated. 
Eleven (16%) of the protocols described trials where we 
found the information insufficient to judge if the trial was 
ethically justified, either due to a comparator that was 
not supported by the presented evidence (six protocols), 
because they did not present a rationale for conducting the 
trial (two protocols), or for both reasons (three protocols). 
For eight (12%) of the protocols, our search identified trials 
that could have been relevant to cite as justification.
Conclusions While most protocols seem to adequately 
consider existing evidence, a substantial minority of trials 
might lack a sufficient evidence base. Very few trials 
seemed to have been based on a literature search which 
makes it impossible to know whether all relevant previous 
trials had been considered. Rules for ethical approval 
should include requirements for systematic literature 
searches to ensure that research participants are not 
exposed to sub- optimal treatments or unnecessary harms 
as well as to reduce research waste.
IntrODuCtIOn
Medical research involving humans must 
meet high ethical standards. The Declaration 
of Helsinki specifies that a research project 
should only be carried out ‘if the importance 
of the objective outweighs the risks and 
burdens to the research subjects’.1 As a prereq-
uisite, the Declaration underlines that trial 
participants are properly informed about the 
harms and benefits of the studied interven-
tions. Similar requirements are found in the 
European Clinical Trials Directive2 and in the 
Good Clinical Practice guidelines published 
by the European Medicines Agency.3 It follows 
that before a new trial is undertaken, knowl-
edge gained from previous similar trials needs 
to be considered for trial planning and must 
also be communicated to the participants.
In 2013, the Standard Protocol Items: 
Recommendations for Interventional Trials 
statement was published. It outlines 33 items 
(with sub- items) that should be adequately 
reported in clinical trial protocols. Item 
six is ‘Background and Rationale’ which 
describes the importance of justifying a new 
trial in the context of the available evidence. 
It is ‘strongly recommended that an up-to- 
date systematic review of relevant studies be 
summarised and cited in the protocol’.4
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In Denmark, a systematic literature review is not 
required in protocols for randomised trials although the 
Danish Medicines Agency state in their guidelines for 
applications for clinical trials that relevant results from 
previous clinical and non- clinical studies must be reported 
in trial protocols.5–7 For decades, researchers have argued 
that in order for a study to be scientifically and ethic- 
ally justifiable its design should take previous research 
into consideration based on a systematic review.8 9 We 
obtained a cohort of trial protocols approved by one of 
the five regional research ethics committees in Denmark 
and used this cohort to study whether the ethical approval 
system ensures that trials justify their scientific rationale 
and use of comparators based on previous trials and take 
their results, whether positive or negative, into account.
MethODS
Access to trial protocols is possible through the Danish 
Freedom of Information Act. Between 1 October 2013 
and 28 February 2014, we screened the titles of all 
research projects approved by either one of the five 
regional ethics committees in Denmark between January 
2012 and March 2013. The research projects could be 
found on the website of the Danish National Committee 
on Health Research Ethics which functions as a common 
web- page for all five regional committees. Eligible proto-
cols were then requested from the ethics committees.
Inclusion and exclusion criteria
A protocol was eligible if it described a randomised, 
parallel group trial and had prespecified non- surrogate 
primary outcomes. We excluded trials with only surrogate 
outcomes as determining the relevance of such outcomes 
to patients require detailed content area knowledge from 
diverse fields. We also excluded trials that could not be 
identified via trial registries as our initial assessment of 
eligibility was based on information from these registries.
As we identified substantially more eligible trials than 
we could realistically extract data from, we limited our 
predefined period of inclusion to 1 October 2012 to 31 
March 2013.
The website of the ethics committees only contained 
information on the date of approval, the project title, the 
Danish region where the trial would take place and the 
name of the coordinating investigator. We sought addi-
tional information (described below) about the research 
projects through  clinicaltrials. gov, the EU Clinical Trials 
Register (EudraCT) and the WHO International Clin-
ical Trial Registry Platform using information from the 
website of the ethics committee (for example, interven-
tion or a trial identifier found in the project title). If we 
were unable to identify the eligible studies in trial regis-
tries, we attempted to identify a trial ID through Google 
searches using the information from the committee’s 
website. Trial characteristics from these registries were 
extracted, and eligibility was assessed by one observer. We 
extracted information on the following characteristics: 
study type, design, population, interventions, inclusion 
and exclusion criteria of the trial, primary outcomes and 
desired sample size. When there was uncertainty about 
eligibility, a second observer was consulted.
For trials that we considered potentially eligible based 
on information from trial registries, we contacted the 
relevant regional ethics committee and requested copies 
of the protocols, informed consent forms, financial and 
publication agreements between the study sponsors and 
the investigators, and any other relevant information 
about the trials, for example, the investigators' brochure. 
We emphasised that the results would be published in a 
manner that would not allow identification of individual 
trials.
Based on the protocols, we made a final assessment of 
eligibility and assigned each trial a unique, anonymised 
identifier.
Data extraction
As the protocols were long and contained much informa-
tion irrelevant to our project, one observer entered appli-
cable text into a Word document. The introduction or 
background section as well as any sections of the protocol 
addressing ethical issues or clinical information on the 
used interventions were extracted this way. All subjective 
judgements based on the extracted texts were performed 
by two observers independently and all ambiguities or 
disagreements were discussed, if necessary involving a 
third observer.
Additionally, all trials where the choice of treatment 
and comparator could be questioned were discussed with 
a senior researcher. Our assessments were entered into a 
standardised data extraction sheet.
Any information in the protocols about the source 
of funding and the type of comparator used were also 
extracted from the protocol and entered into the data 
extraction sheet.
Funding issues
A trial was considered fully industry sponsored when a 
commercial company was listed as the primary or only 
sponsor; partially industry sponsored when the primary 
sponsor was a non- commercial entity but a commercial 
company provided either funding, devices, medications, 
manpower or similar to the project; and non- industry 
funded when the sponsor was a non- commercial entity 
and no commercial funding, devices, medications, 
manpower or similar was received.
Type of comparator
The type of comparator used in the control arm was 
classified as either an active comparator, placebo or 
‘nothing’. In trials that used a comparator classified 
as ‘nothing’ participants received either no treatment 
or were put on a waiting list. Trials with more than two 
arms could use more than one type of comparator; in 
this case we classified a trial as using a combination of 
the above, for example, a trial could be classified as 
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Figure 1 Flow chart of included studies.
having a placebo arm as well as an active comparator 
arm. Comparators described in the protocol as ‘usual/
standard care’ could be either ‘active treatment’ or ‘no 
treatment’ and was classified according to the descrip-
tion in the protocol.
Justification for choice of comparator
We noted whether the choice of comparator in the indi-
vidual protocol was justified as recommended in the 
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) reporting guidelines.4 10 We distin-
guished between an explicit and an implicit justification.
We defined that a protocol explicitly justified the choice 
of comparator when a specific reason for the choice was 
given, for example, a section such as ‘Rationale for choice 
of comparator’ or statements such as ‘Regarding justifica-
tion of placebo: "Placebo is the appropriate comparator, 
since the approved therapies available in some countries 
are not routinely used for treatment of lower- risk disease."’
The justification for choice of comparator was consid-
ered implicit when, for example, the control group was 
stated to simply receive the usual standard of care or 
when there was documented uncertainty about which of 
two active interventions was superior.
Literature search
We noted whether it was stated or implied in protocols 
and related documents whether a systematic literature 
search had been performed and if search strings, restric-
tions, filters, dates for searches and names of databases 
were described.
Citations of relevant trials or systematic reviews
We read the included protocols in full and checked their 
references to identify trials of similar interventions, for 
similar indications and in similar populations. We also 
checked all references in any systematic reviews that were 
cited in the protocol to see if these identified relevant 
trials. When we checked the existing trials and system-
atic reviews, we looked for both evidence on benefits and 
harms.
Our searches for relevant trials
For each protocol, we conducted systematic searches to 
identify additional randomised trials or systematic reviews 
that could have been relevant to cite in the protocols. We 
restricted the study design to randomised trials when 
searching and we used simple and broad search strategies 
that could have been performed by researchers without 
experience with systematic literature searches. We 
searched PubMed and EMBASE and the search strings 
followed a general template:
 ► [Indication] AND [intervention]
For example, the following search string was used for a 
study of the use of surgical mesh in inguinal hernia oper-
ations: inguinal hernia AND mesh AND fixation.
All searches were restricted to publications entered into 
the databases at least one month before the first submis-
sion of the protocol to the research ethics committee. 
We screened titles and abstracts from our searches and 
potentially eligible trials were read in full text to assess 
their relevance.
Analysis
We compared the references in the protocols with the 
results of our own systematic search.
We deemed a comparator questionable if:
 ► One or more previous randomised trials conducted 
with the same intervention, for the same condition 
and using the same outcome had found that the inter-
vention was superior to the proposed comparator and 
the choice was not further justified in the protocol.
We deemed the rationale for conducting a study ques-
tionable if a protocol did not provide any evidence of clin-
ical equipoise to justify a randomised controlled trial. We 
based this judgement on the principles outlined in item 
6A of the SPIRIT statement4 and in the SPIRIT explana-
tion and elaboration paper10 where it is explained that 
a protocol should ‘summarise the importance of the 
research question, justify the need of the trial in the 
context of available evidence, and present any available 
data regarding the potential effects of the interventions 
(benefits and harms)’.4 10 Thus we examined if protocols:
 ► Identified a lack of studies of direct relevance.
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Table 1 Prespecified sample size by type of funding
Patients 
included
Fully industry 
sponsored 
(n=33)
Partially industry 
sponsored (n=10)
Non- 
industry 
sponsored 
(n=24)
Range 91–18 000 80–2314 30–2844
Median 620 311 95
Mean 1799 612 414
 ► Established that results of previous studies were 
inconclusive.
We also considered whether the choice of outcomes 
and methodology (for example, timing of treatment) was 
appropriate for the scientific question posed, based on 
the available evidence.
For both the justification of comparators and the scien-
tific rationale for the research question, we did not judge 
whether a trial was unethical but examined whether the 
information presented would enable ethics committees 
to evaluate if the trials were justified.
For studies where we found insufficient information, 
we summarised the reasons in a tabular format.
Patient and public involvement
Patients were not involved in this study.
reSultS
Screening and retrieval of protocols
The regional ethics committees approved a total of 1401 
protocols between 1 January 2012 and 31 March 2013. We 
excluded 1189 protocols either because the trials could 
not be identified in trial registries or via Google searches 
(n=794) or because they did not fulfil our eligibility 
criteria (n=395). This is summarised in figure 1.
The remaining 212 protocols all seemed to describe 
trials with a randomised parallel group design and patient 
relevant outcomes, based on the available information. As 
our desired sample size was 60 protocols we excluded all 
trials approved prior to October 2012 which limited our 
sample to 78 protocols. We applied to the committees for 
full access to the protocols and any related documents.
Even though we stressed in our application that results 
of this project would be published in a way that would not 
allow identification of individual trials access was initially 
denied or the protocols were redacted for 25 trials (37%). 
Details of the redactions in protocols for trials that were 
industry sponsored are published elsewhere.11 We gained 
access to the full unredacted protocols after an appeal 
to the Danish National Committee on Health Research 
Ethics, a process which took several years and involved 
lawyers. This process is also described elsewhere.11
After reading the documents we had received, we 
excluded 11 trials because it turned out they either did 
not use a parallel group design (n=4), only used surrogate 
primary outcomes (n=6) or was a duplicate (n=1). This 
led to our final sample of 67 eligible protocols.
Study characteristics
Of the 67 included protocols, 33 (49%) were for fully 
industry sponsored trials, 10 (15%) were partially industry 
sponsored, and 24 (36%) were non- industry sponsored. 
Thirty of the fully industry sponsored trials (91%) were 
multinational, in contrast to five partially industry spon-
sored trials (50%) and three non- industry sponsored 
trials (13%).
The prespecified sample sizes in the protocols ranged 
from 30 to 18 000 patients (mean 1124, median 400). 
Industry sponsored trials generally had considerably 
larger sample sizes than trials with no or partial industry 
funding (see table 1).
Nineteen protocols (28%) described trials in oncology 
and 10 protocols (15%) surgical interventions. The 
specialities of the remaining 38 protocols can be seen in 
table 2.
Comparators
Placebo was the only comparator in 18 (27%) of the trials. 
Thirty- two trials (48%) used active comparators only and 
10 trials (15%) used no treatment as the only comparator. 
Six trials (9%) used both a placebo- arm and an arm with 
an active comparator. One trial (1%) used both an active 
comparator arm and an arm with no treatment.
Twenty protocols (30%) described the comparator as 
‘usual care’ which in 18 cases was an active comparator 
and in two was no treatment.
The protocol authors justified their choice of compar-
ator in 42 protocols (63%). The justification was explicit 
in 21 protocols and implicit in 21, for example, by 
mentioning that participants in the control group would 
receive ‘standard care’.
We identified 11 protocols (16%) where the choice 
of treatment or comparator could be questioned given 
the evidence available at the time and the information 
provided in the protocols. The reasons for our judge-
ments are described in box 1.
literature searches described in protocols and comparison 
with our search results.
Only 2 (3%) of the 67 protocols explicitly stated to have 
conducted a literature search and only one of these 
provided full information that allowed the search to be 
replicated. The other protocol disclosed only when the 
search was performed and the databases searched; there 
were no search strings or information on any restric-
tions used. Four additional protocols used phrases indi-
cating that a literature search may have been done, for 
example, ‘Review of literature… suggest’, ‘According to 
searches on the PubMed database’, ‘Unfortunately only 
a few studies examine the effect of MP on acute pain… 
(PubMed search Feb. 2012)’ and ‘A review of the litera-
ture thus indicates…’.
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Table 2 Medical specialities of included protocols
Speciality Protocols, n (%)
Oncology 19 (28)
Surgery 10 (15)
Obstetrics and gynaecology 7 (10)
Rheumatology 6 (9)
Anaesthesia 5 (7)
Cardiology 5 (7)
Endocrinology 5 (7)
Dermatology 2 (3)
Gastroenterology 2 (3)
Psychiatry 2 (3)
Pulmonary medicine 2 (3)
Geriatrics 1 (1)
Paediatrics 1 (1)
box 1 examples of studies where the justification could 
be challenged, based on the information available in the 
protocols.
 ► A study examined the effect of a procedure on the fertility rate. The 
control group did not get a procedure that the protocol authors de-
scribed as the gold standard.
 ► A phase 3 study was initiated before phase 2 studies were com-
pleted although the studied drug belonged to a class known to be 
quite toxic.
 ► A study examining treatment for serious cardiovascular disease 
used a bare metal stent as comparator, even though a systematic 
review found that a drug- coated stent was more effective regarding 
the primary outcome of the study.
 ► A study examining the effect of a special form of exercise used 
a control group that received no intervention even though the ef-
fects of exercise on the primary outcome (quality of life) were well 
established.
 ► A study compared ‘liberal’ and ‘restrictive’ red blood cell trans-
fusion practices despite citing a systematic review which found 
that, ‘According to the results of the largest RCT, maintaining a 
higher haemoglobin level… seems to confer little clinical benefit.’ 
Furthermore, it has been shown that blood transfusions carry im-
portant harms.
 ► A study compared a training programme that started in the hos-
pital and continued at home with usual practice (ie, very little re-
habilitation) in elderly patients. The benefits of training were well 
established.
 ► A study convincingly established that a special diet is effective in 
reducing postoperative infections but the most effective timing of 
intervention had yet to be established; however, preoperative ad-
ministration of the diet was compared with usual diet rather than a 
different timing of the diet.
 ► A study examining relapse free survival for a type of cancer com-
pared an investigational drug with observation only although other 
treatments had shown effects on the primary outcome when com-
pared with observation only.
 ► Three studies examined the efficacy of analgesic drugs or tech-
niques and used placebo as comparator, although other treatments 
had been proven effective. All the studies allowed for the use of 
rescue medication in some form, but it was clear that patients in the 
placebo groups received sub- optimal treatment.
Thus, if very broad criteria are applied, the protocol 
authors did a literature search in six cases (9%).
Twelve protocols (18%) cited either a systematic review 
or a randomised trial with clear, direct relevance for the 
intervention, population and/or indication studied. Two 
protocols (3%) cited one or more systematic reviews, eight 
protocols (12%) cited one or more randomised trials and 
two protocols (3%) cited both systematic reviews and 
randomised trials. For 11 of these 12 protocols (92%), we 
did not find additional relevant trials through our own 
systematic search. For the remaining one protocol (8%), 
we identified one systematic review and two randomised 
trials (819 included trial participants) that could have 
been relevant to cite.
The remaining 55 protocols (82%) cited no relevant 
systematic reviews or randomised trials. However, for 48 of 
these 55 protocols (87%), we did not identify any studies 
that could have been cited. For the remaining seven 
protocols (13%), we identified 10 randomised trials and 
one systematic review (with a total of 2080 included trial 
participants) that could have been cited. These results are 
summarised in table 3.
DISCuSSIOn
Principal findings
We found that only one (1%) of the 67 included protocols 
described a reproducible systematic search for previous 
randomised trials of the same intervention. Even when 
applying very broad criteria, only six (9%) protocols indi-
cated that a search may have been carried out, whether 
systematic or not. We found 12 (18%) protocols that cited 
relevant systematic reviews or randomised trials. The 
remaining 55 (82%) protocols cited no such evidence but 
our own searches did not identify any relevant systematic 
reviews or randomised trials for 48 of them.
Sixteen percent of included trial protocols either 
did not present a rationale for conducting the study or 
used comparators that could be questioned based on 
the evidence available at the time and did not provide 
information to explain these choices. While these trials 
may be ethically acceptable, we were unable to confirm 
this based on the information available in the protocols. 
Thus, a considerable number of research participants 
could potentially have been exposed to sub- optimal treat-
ment or unnecessary inconvenience, discomfort or risk 
of harm.
A systematic search for previous trials is not an explicit 
requirement for ethical approval in Denmark but it is 
difficult to see how researchers can know whether rele-
vant previous trials exist without performing a systematic 
search, especially considering the high number of new 
publications today. In 2010, a study found that 75 reports 
of trials and 11 systematic reviews were published every 
day and these numbers had been rising.12
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Table 3 Citations of trials and reviews of direct relevance
Cited trials or reviews of direct 
relevance and no additional studies 
were identified
11 protocols (16%)
Cited no trials or reviews of direct 
relevance and no relevant studies were 
identified
48 protocols (72%)
Protocols where no additional 
relevant trials or reviews were 
identified through our searches
59 protocols (88%)
Cited trials or reviews of direct 
relevance, but additional relevant 
studies were identified
1 protocol (1%)
Cited no trials or reviews of direct 
relevance, but relevant studies were 
identified
7 protocols (11%)
Protocols where additional relevant 
trials or reviews were identified 
through our searches
8 protocols (12%)
Total 67 protocols 
(100%)
Although conducting trials on topics where previous 
trials exists can be warranted (eg, to replicate findings 
or when a previous trial could not answer the research 
question due to either size or quality), there is evidence 
that superfluous trials represent a considerable waste 
of resources, both in terms of financial and intellectual 
resources.13 A formal requirement for systematic searches 
in trial protocols may reduce this waste.
Comparisons with other studies
There are historical cases of superfluous trials, for 
example, of intravenous streptokinase as thrombolytic 
treatment. In 1992, a cumulative meta- analysis showed 
that in 1973, after just eight trials of 33 total performed 
since the late 1950s, a consistent and statistically significant 
reduction in total mortality was shown. The remaining 25 
trials (with a total of 34 542 participants enrolled) had 
little effect on the OR and only narrowed the CI.14 Still, 
new trials of the intervention were performed until the 
late 1980s. As meta- analyses were not routinely used at 
this point in time, we should not judge this by modern 
standards. However, it highlights the importance of exam-
ining existing evidence before conducting a new trial.
Several previous studies have examined published 
protocols to assess if they live up to ethical requirements. 
In 2016, a study found that 41% of 101 trial protocols 
cited any randomised trial or a systematic review, whether 
the trials addressed a similar question or not.15 We found 
that only 18% of protocols cited a randomised trial, which 
may be because we only included trials that we found to 
be of direct relevance for the protocol. Additionally, the 
2016 study included only published protocols whereas we 
included any protocol given ethical approval.
Several studies have investigated whether publications 
of randomised trials reference previous trials, and it has 
repeatedly been shown that this is often not the case. In 
2011, a study of 1523 trials found that less than a quarter 
of the relevant previous trials were cited, and that for 
the 1101 RCTs where five or more previous trials could 
have been cited, 23% cited no trials and another 23% 
cited only one.16 In 2010, Clarke et al. reproduced their 
previous findings from 1997, 2001 and 2005 that most 
reports of trials fail to cite updated systematic reviews 
when discussing their results.9
Strengths and limitations
To our knowledge, this is the first cohort of contempo-
rary protocols approved by an ethics committee that have 
studied whether they live up to the ethical standards 
expressed in the Declaration of Helsinki.1 We chose to 
be conservative when judging whether the choice of 
comparator was reasonable given existing evidence for 
potentially effective treatments and whether an evidence 
base supporting the rationale for the investigated treat-
ment was provided, because such assessments are inevi-
tably subjective.
Our included protocols are over five years old but as 
systematic literature searches are still not mandatory for 
approval of protocols in Denmark, our results are likely 
valid today. Ethics committees in Denmark now have 
access to the investigators’ brochure which might contain 
some of the information we looked for but did not find.
Some of the protocols in our sample described trials 
involving medications or devices at an early stage of devel-
opment and for such trials systematic reviews are unlikely 
to exist. However, a systematic search could still be relevant 
as similar interventions may have been tested. In 2006, 
six participants developed multiple organ failure after a 
phase 1 trial in the UK, and it has been suggested that 
a systematic review of preclinical and clinical data could 
have predicted the life- threatening adverse effects.17 18
We did not search for unpublished trials in our own 
systematic searches. Publication bias is a significant 
problem in medical research,19 and trials with posi-
tive results are more likely to be published. Thus, 
there could be relevant studies that we did not identify. 
However, expecting protocol authors to find these may 
be unreasonable.
We did not search for observational studies, although 
they can be important for detecting rare or unexpected 
harms. It is therefore possible that we would have found 
additional interventions or comparators to be problem-
atic, had we included such studies
Finally, the reporting and reproducibility of our study is 
limited by the confidentiality agreements signed in order 
to obtain access to protocols.
Implications for practice and research
Other researchers have highlighted problems with the 
current system of ethical approval and shown examples 
of cases where unethical studies were granted ethical 
approval.15 20 Our review supports the need for policy 
changes.
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We suggest that protocols and other documents should 
be made publicly available as soon as the protocol has 
received ethical approval. These documents are currently 
very difficult to get access to, especially for trials with 
commercial sponsors.10 Access to such documents is of 
vital public interest as it is the public that participate in 
trials, and the safety and rights of research participants 
should be weighted higher than commercial interests. 
Indeed, commercial interests are likely not at stake as 
trial protocols rarely contain commercially sensitive 
information.21
We also propose a requirement to conduct a system-
atic literature search prior to applications for ethical 
approval. In 2005, The Lancet made it a requirement for 
authors of clinical trials to include a clear summary of 
previous research and explain how their trial results affect 
the summary.22 In 2010, the executive editor and editor- 
in- chief of the Lancet commented on the disappointing 
implementation of this policy and made the policy more 
specific by requiring that authors either conduct their 
own systematic review or cite a recent systematic review 
and put their own trial results into this context.23 Almost 
no other journals have a similar policy and the respon-
sibility to safeguard the rights of participants should be 
shared with ethics committees.
Lastly, we recommend that ethics committees formally 
endorse and apply the SPIRIT statement4 10 which is an 
evidence- based set of items that should be addressed in 
a protocol. We believe all protocols for randomised trials 
submitted to ethics committees should follow the format and 
report on the items presented in the SPIRIT statement.
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